BIOCYTOGEN PHARMA. H YC1 (F:I54) — Market Cap & Net Worth
Market Cap & Net Worth: BIOCYTOGEN PHARMA. H YC1 (I54)
BIOCYTOGEN PHARMA. H YC1 (F:I54) has a market capitalization of $710.19 Million (€607.46 Million) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #10779 globally and #1240 in its home market, demonstrating a -5.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOCYTOGEN PHARMA. H YC1's stock price €5.65 by its total outstanding shares 107515313 (107.52 Million).
BIOCYTOGEN PHARMA. H YC1 Market Cap History: 2022 to 2026
BIOCYTOGEN PHARMA. H YC1's market capitalization history from 2022 to 2026. Data shows growth from $372.06 Million to $710.19 Million (18.38% CAGR).
BIOCYTOGEN PHARMA. H YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOCYTOGEN PHARMA. H YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of I54 by Market Capitalization
Companies near BIOCYTOGEN PHARMA. H YC1 in the global market cap rankings as of May 4, 2026.
Key companies related to BIOCYTOGEN PHARMA. H YC1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BIOCYTOGEN PHARMA. H YC1 Historical Marketcap From 2022 to 2026
Between 2022 and today, BIOCYTOGEN PHARMA. H YC1's market cap moved from $372.06 Million to $ 710.19 Million, with a yearly change of 18.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €710.19 Million | +50.67% |
| 2025 | €471.36 Million | +316.67% |
| 2024 | €113.13 Million | -47.67% |
| 2023 | €216.20 Million | -41.89% |
| 2022 | €372.06 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of BIOCYTOGEN PHARMA. H YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $710.19 Million USD |
| MoneyControl | $710.19 Million USD |
| MarketWatch | $710.19 Million USD |
| marketcap.company | $710.19 Million USD |
| Reuters | $710.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody devel… Read more